Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 131

1.

ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study.

Wilens T, McBurnett K, Stein M, Lerner M, Spencer T, Wolraich M.

J Am Acad Child Adolesc Psychiatry. 2005 Oct;44(10):1015-23. Erratum in: J Am Acad Child Adolesc Psychiatry. 2006 May;45(5):632.

PMID:
16175106
[PubMed - indexed for MEDLINE]
2.

ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study.

Wilens T, Pelham W, Stein M, Conners CK, Abikoff H, Atkins M, August G, Greenhill L, McBurnett K, Palumbo D, Swanson J, Wolraich M.

J Am Acad Child Adolesc Psychiatry. 2003 Apr;42(4):424-33.

PMID:
12649629
[PubMed - indexed for MEDLINE]
3.

A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).

Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ; COMACS Study Group.

Pediatrics. 2004 Mar;113(3 Pt 1):e206-16.

PMID:
14993578
[PubMed - indexed for MEDLINE]
4.

Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.

Fallu A, Richard C, Prinzo R, Binder C.

Curr Med Res Opin. 2006 Dec;22(12):2557-66.

PMID:
17166338
[PubMed - indexed for MEDLINE]
5.

Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.

Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, McBurnett K, Bukstein O, August G.

Pediatrics. 2001 Oct;108(4):883-92.

PMID:
11581440
[PubMed - indexed for MEDLINE]
6.

A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.

Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE.

Can J Clin Pharmacol. 2006 Winter;13(1):e50-62. Epub 2006 Jan 23.

PMID:
16456216
[PubMed - indexed for MEDLINE]
Free Article
7.

Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study.

Remschmidt H, Hoare P, Ettrich C, Rothenberger A, Santosh P, Schmidt M, Spender Q, Tamhne R, Thompson M, Tinline C, Trott GE, Medori R.

Eur Child Adolesc Psychiatry. 2005 Sep;14(6):297-304.

PMID:
16220213
[PubMed - indexed for MEDLINE]
8.

Dose-response characteristics in adolescents with attention-deficit/hyperactivity disorder treated with OROS methylphenidate in a 4-week, open-label, dose-titration study.

Newcorn JH, Stein MA, Cooper KM.

J Child Adolesc Psychopharmacol. 2010 Jun;20(3):187-96. doi: 10.1089/cap.2009.0102.

PMID:
20578931
[PubMed - indexed for MEDLINE]
9.

Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate : a chart review of Spanish adults with attention-deficit hyperactivity disorder.

Ramos-Quiroga JA, Bosch R, Castells X, Valero S, Nogueira M, Gómez N, Yelmo S, Ferrer M, Martínez Y, Casas M.

CNS Drugs. 2008;22(7):603-11.

PMID:
18547128
[PubMed - indexed for MEDLINE]
10.

Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.

Kordon A, Stollhoff K, Niederkirchner K, Mattejat F, Rettig K, Schäuble B.

Postgrad Med. 2011 Sep;123(5):27-38. doi: 10.3810/pgm.2011.09.2457.

PMID:
21904084
[PubMed - indexed for MEDLINE]
11.

Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy.

Palumbo D, Spencer T, Lynch J, Co-Chien H, Faraone SV.

J Child Adolesc Psychopharmacol. 2004 Summer;14(2):185-94.

PMID:
15319016
[PubMed - indexed for MEDLINE]
12.

Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study.

Kemner JE, Starr HL, Ciccone PE, Hooper-Wood CG, Crockett RS.

Adv Ther. 2005 Sep-Oct;22(5):498-512.

PMID:
16418159
[PubMed - indexed for MEDLINE]
13.

Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder.

Wigal SB, Gupta S, Heverin E, Starr HL.

J Child Adolesc Psychopharmacol. 2011 Jun;21(3):255-63. doi: 10.1089/cap.2010.0083.

PMID:
21663428
[PubMed - indexed for MEDLINE]
14.

A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.

Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T.

Biol Psychiatry. 2006 May 1;59(9):829-35. Epub 2005 Dec 20. Erratum in: Biol Psychiatry. 2007 Jun 15;61(12):1402.

PMID:
16373066
[PubMed - indexed for MEDLINE]
15.

Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.

Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T.

J Clin Psychopharmacol. 2009 Jun;29(3):239-47. doi: 10.1097/JCP.0b013e3181a390ce.

PMID:
19440077
[PubMed - indexed for MEDLINE]
16.

Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.

Niederkirchner K, Slawik L, Wermelskirchen D, Rettig K, Schäuble B.

Expert Rev Neurother. 2011 Apr;11(4):499-508. doi: 10.1586/ern.11.18.

PMID:
21469923
[PubMed - indexed for MEDLINE]
17.

12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH.

Hoare P, Remschmidt H, Medori R, Ettrich C, Rothenberger A, Santosh P, Schmit M, Spender Q, Tamhne R, Thompson M, Tinline C, Trott GE.

Eur Child Adolesc Psychiatry. 2005 Sep;14(6):305-9.

PMID:
16220214
[PubMed - indexed for MEDLINE]
18.

[Switching from a short-acting to a long-acting methylphenidate preparation: a multicentre, open study in children with ADHD].

Heger S, Trott GE, Meusers M, Schulz E, Rothenberger A, Rettig K, Medori R, Schreiner A, Remschmidt H; Vertreter der deutschen C-2000-045-Studiengruppe.

Z Kinder Jugendpsychiatr Psychother. 2006 Jul;34(4):257-65. German.

PMID:
16927568
[PubMed - indexed for MEDLINE]
19.
20.

Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder.

McGough JJ, McBurnett K, Bukstein O, Wilens TE, Greenhill L, Lerner M, Stein M.

J Child Adolesc Psychopharmacol. 2006 Jun;16(3):351-6.

PMID:
16768642
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk